AGREEMENT AND PLAN OF MERGERMerger Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 29th, 2021 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 29, 2021, is entered into by and among Millendo Therapeutics, Inc., a Delaware corporation (“Public Company”); Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company (the “Merger Sub”); and Tempest Therapeutics, Inc., a Delaware corporation (“Merger Partner”).
form of Merger partner SUPPORT AGREEMENTMerger Partner Support Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 29th, 2021 Company Industry JurisdictionThis Support Agreement (this “Agreement”) is made and entered into as of March [●], 2021, by and among Tempest Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Millendo Therapeutics, Inc., a Delaware corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Merger Partner.
form of Public COMPANY SUPPORT AGREEMENTSupport Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 29th, 2021 Company Industry JurisdictionThis Support Agreement (this “Agreement”) is made and entered into as of [●], 2021, by and among Tempest Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Millendo Therapeutics, Inc., a Delaware corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Public Company.
LOCK-UP AGREEMENTLock-Up Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 29th, 2021 Company Industry JurisdictionThe undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Millendo Therapeutics, Inc., a Delaware corporation (“Public Company”), has entered into an Agreement and Plan of Merger, dated as of [●], 2021 (as the same may be amended from time to time, the “Merger Agreement”) with Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company, and Tempest Therapeutics, Inc., a Delaware corporation. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.